MA09-hRPE

Biologic

Astellas

MA09-hRPE is one of 5 biologic programs targeting Dry Age Related Macular Degeneration. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Age Related Macular DegenerationActive, not recruiting

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Dry Age Related Macular Degeneration

#DrugCompanyPhaseTrials

Copaxone

Retaane

PST-611

1 4

GEM103

GGemini Therapeutics, Inc.

Phase 1

1 5

MA09-hRPE

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplantation3 trials

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

Completed· Astellas logo

Astellas·Phase 1/2·NCT01345006·13 enrolled

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Completed· Astellas logo

Astellas··NCT02463344·11 enrolled

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Completed· Astellas logo

Astellas·Phase 1/2·NCT01469832·12 enrolled

Stargardt1 trial

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Completed·CCHABiotech CO., Ltd·Phase 1·NCT01625559·3 enrolled

Dry Age Related Macular Degeneration1 trial

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration

Completed· Astellas logo

Astellas·Phase 1/2·NCT01344993·13 enrolled

phaseI/II1 trial

A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD

Terminated·CCHABiotech CO., Ltd·Phase 1/2·NCT01674829·10 enrolled

Stargardt Macular Dystrophy1 trial

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Completed· Astellas logo

Astellas··NCT02445612·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MA09-hRPE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MA09-hRPE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MA09-hRPE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Astellas

MA09-hRPE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplantation3 trials

Stargardt1 trial

Dry Age Related Macular Degeneration1 trial

phaseI/II1 trial

Stargardt Macular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News